Invega Sustenna is a long-acting injectable antipsychotic medication [1]. It is a brand-name drug containing the active ingredient paliperidone palmitate [1][2]. The medication is administered as a slow-release injection, meaning it is gradually absorbed into the body over an extended period [1]. This formulation is designed to improve treatment adherence for patients with certain mental health conditions [1][3].
How does Invega Sustenna work?
Invega Sustenna works by releasing paliperidone palmitate slowly after injection [1]. Paliperidone is an atypical antipsychotic that affects dopamine and serotonin neurotransmitters in the brain [4]. By stabilizing these neurotransmitters, it can help manage symptoms of conditions like schizophrenia and schizoaffective disorder [4][5]. The long-acting nature of the injection allows for less frequent dosing compared to daily oral medications [1][3].
What conditions is Invega Sustenna used to treat?
Invega Sustenna is approved for the treatment of schizophrenia in adults [5]. It is also used for the treatment of schizoaffective disorder in adults [5]. The medication is typically part of a broader treatment plan that may include psychotherapy and other support services [4].
How often is Invega Sustenna injected?
Invega Sustenna is administered as an intramuscular injection [1]. Initially, patients receive a starter injection followed by a dose one week later [1]. After these initial doses, subsequent injections are given once every month [1][5].
What are the potential side effects of Invega Sustenna?
Like all medications, Invega Sustenna can cause side effects [6]. Common side effects include injection site reactions such as pain or redness, and systemic effects like drowsiness, dizziness, and weight gain [6]. Other potential side effects can include movement disorders (e.g., tardive dyskinesia), increased prolactin levels, and changes in heart rhythm [4][6]. Patients should discuss any concerns about side effects with their healthcare provider [6].
Can Invega Sustenna be used by children or adolescents?
Invega Sustenna is approved for use in adults [5]. Its use in pediatric populations has not been established [5].
What is the difference between Invega Sustenna and Invega Trinza?
Invega Sustenna is a long-acting injectable that is administered monthly [1]. Invega Trinza is another long-acting injectable formulation of paliperidone palmitate, but it is designed for less frequent dosing, typically administered every three months [7]. Both medications are used for the treatment of schizophrenia [5][7].
When does the patent for Invega Sustenna expire?
Information regarding the specific patent expiry dates for Invega Sustenna can be found on resources like DrugPatentWatch.com [8]. Patent exclusivity periods determine when generic versions of a drug may become available [8].
Who manufactures Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1][9].